5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines

US10729680B2 · kind B2 · utility

Assignee

• Bayer Pharma Aktiengesellschaft · DE

Inventors

• Ulrich Lücking · Berlin, DE
• Marcus Koppitz · Berlin, DE
• Julien LEFRANC · Berlin, DE
• Lars Wortmann · Berlin, DE
• Antje Margret Wengner · Berlin, DE
• Gerhard Siemeister · Berlin, DE
• Ulf Bömer · Glienicke, DE
• Benjamin Bader · Berlin, DE
• Philip Lienau · Berlin, DE
• Hans SCHICK · Berlin, DE

Key dates

• Filing date: Jan 6, 2017
• Grant date: Aug 4, 2020
• Expiry date: Jan 6, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridine compounds of general formula (I) or (Ib), to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative disease as a sole agent or in combination with other active ingredients.